“We believe we will offer in a year’s time a complete cure for cancer,” Dan Aridor of Accelerated Evolution Biotechnologies (AEBi), the biopharmaceutical company who discovered and engineered the new therapy, told the Jerusalem Post. “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.”
MuTaTo works as a cancer-cell specific toxin that destroys several aspects of the protein structures (receptors) of cancer cells simultaneously, making it harder for the cells to mutate and evade cellular death.
"We didn't want to have another drug like everyone else that would give relief to some cancer patients and then the cancer would come back. We wanted really to cure something like antibiotics," Dr. Ilan Morad, CEO of AEBi, told CBN News. "Because, you know, HIV is very mutagenic creature, same as cancer. This is the problem with cancer. It is very mutagenic and these mutations help the cancer escape the therapy.
"The main thing here is the multiple targeting,” Dr. Morad continued. “So instead of attacking one target at a time we connect together several peptides and we attack several targets at a time. And because of that, the cancer won't be able – statistically – it won't be able to escape the therapy and this is what happened with AIDS. And this is what would happen here in cancer."
There has been no shortage of criticism and skepticism in the international scientific and medical communities, but the company believes in its product and its potential for saving lives.
"I don't care about money,” Dr. Morad said. ”I just want to cure cancer patients."
Written by Erin Parfet
